HomeACADEMIA
ACADEMIA

Victoza 1st GLP-1 Agent to Thwart Cardiovascular Events; Will It Catch on?
(Jun.15.2016)

Novo Nordisk’s Victoza (liraglutide) became the first glucagon-like peptide-1 (GLP-1) receptor agonist to demonstrate reductions in cardiovascular risks in diabetes patients, and the second diabetes drug to do so, after Jardiance (empagliflozin), with a reduction of 13%, according to its outcome trial data ...
(LOG IN FOR FULL STORY)

News Calendar